Business Context and Reporting Period
Company: BioCardia, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 16, 2025
Reporting Period: Specific event date (July 16, 2025)
This filing reports a specific corporate event under Item 8.01 (Other Events) regarding the expansion of a clinical trial. It does not cover a standard financial reporting period (quarter or year).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is an event-driven report and does not contain financial statements or performance metrics.
Material Changes
Clinical Trial Expansion: Henry Ford Health in Detroit, Michigan, has begun enrolling patients with ischemic heart failure into BioCardia's ongoing pivotal Phase 3 CardiAMP HF II trial. This represents a material operational development in the company's clinical pipeline.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the trial enrollment but does not include specific forward-looking guidance, financial outlook, or detailed risk factors within the text of the 8-K itself.
Legal Disclaimer: The information furnished in Item 8.01 and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the scope of enrollment at Henry Ford Health.
- Confirm the current status and timeline of the Phase 3 CardiAMP HF II trial in recent 10-Q or 10-K filings.
- Review the company's cash runway and funding status in the most recent quarterly report, as this filing contains no financial data.
- Monitor subsequent filings for updates on patient enrollment rates and trial milestones.